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Ocular toxoplasmosis is the most common cause of posterior uveitis worldwide. The infection can be acquired 
congenitally or postnatally and ocular lesions may present during or years after the acute infection occur. Current 
treatment controls ocular infection and inflammation, but does not prevent recurrences. We present a review and 
update on ocular toxoplasmosis and address misconceptions still found in the current medical literature.
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Ocular toxoplasmosis is caused by the protozoan 
parasite Toxoplasma gondii. Infections may be acquired 
congenitally or through the ingestion of uncooked and 
infected meat, contaminated vegetables or water (Sil-
veira et al. 1988). 
T. gondii infects up to a third of the world’s popu-
lation and is responsible for the majority of infectious 
uveitis (intra ocular inflammation) cases. In some coun-
tries, up to 50% of all cases of posterior uveitis in a given 
population are attributable to toxoplasmosis (Soheilian 
et al. 2004, Vallochi et al. 2005).
The population structure of T. gondii is highly clonal. 
There are three predominant clonal lineages in North 
America and Europe, namely I, II and III. The lineages 
are based on murine model virulence studies (Howe & 
Sibley 1995). It has been suggested that the type II clonal 
lineage of T. gondii may be responsible for the majority 
of acquired ocular lesions, while type I may be more fre-
quently seen in congenital toxoplasmosis. Recently, it has 
been shown that type I as well as atypical strains may play 
an important role in acquired infection (Howe & Sibley 
1995, Belfort-Neto et al. 2007).
Type II strains appear to be responsible for the ma-
jority of symptomatic human cases in France and the 
United States (Nowakowska et al. 2006), while types I 
and III are found in only 10% and 9% of Toxoplasma 
isolates from patients, respectively (Howe et al. 1997). 
In Brazil, type I strains appear to be responsible for 
ocular infections in human patients (Vallochi et al. 2005). 
De Moura et al. (2006) showed that parasites isolated 
from contaminated water in the Southern state of Paraná 
were type I. Another recent publication analyzing sam-
ples from Brazilian patients suggests a cloning diversity 
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when compared with strains from North America and 
Europe (Khan et al. 2006). The city of Erechim, in the 
South of Brazil, has a 17% prevalence of ocular toxo-
plasmosis, and type I T. gondii predominates (Jones et al. 
2006). The genotypes of T. gondii strains isolated from 
São Paulo and Erechim (Brazil) were highly atypical 
when compared with the previously described cloning 
lineages reported in the literature (Khan et al. 2006).
Genotyping of T. gondii in 24 chickens from the Ama-
zon, Brazil, indicated that 14 were type I and 10 were type 
III, confirming that strains in Brazil are divergent from 
European or North American strains (Dubey et al. 2006).
In Erechim, samples from porcine tongues and dia-
phragms were obtained in both large and small abattoirs 
and tested for T. gondii. The results indicated a high 
prevalence of infection and suggested that unusual gen-
otypes of T. gondii are also found in Brazil among do-
mesticated pigs (Belfort-Neto et al. 2007). In that area, 
according to an epidemiological survey, risk factors for 
acquiring toxoplasmosis include eating undercooked 
meat, working in the garden or yard more than once per 
week, eating raw, cured, dried or smoked meat and being 
a male (Jones et al. 2006). 
The genetic makeup of T. gondii is more complex 
than the three-strain theory and unusual genotypes may 
contribute to various clinical outcomes of toxoplasmosis 
in different localities. Variant alleles have also been as-
sociated with severity of pathology. The study of parasite 
genetic backgrounds is important for understanding the 
establishment of ocular disease (Vallochi et al. 2008).
Ocular manifestations and diagnosis
Toxoplasmic retinochoroiditis is often seen in set-
tings of congenital or postnatally acquired disease as a 
result of acute infection or recurrence (Nussenblatt & 
Belfort 1994, Montoya & Remington 1996). This disease 
typically affects the posterior pole of a single eye and 
the lesions can be solitary, multiple or satellite to a pig-
mented retinal scar (Fig. 1). 
Active lesions present as grey-white focuses of retinal 
necrosis with adjacent choroiditis, vasculitis, haemor-
rhage and vitreitis (Figs 2-4). Cicatrization occurs from 
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the periphery towards the centre, with variable pigmen-
tary changes. Anterior uveitis is another common find-
ing, with mutton-fat keratic precipitates, cells and flare, 
and posterior synechiae (Nussenblatt & Belfort 1994).
The retina is the primary site of T. gondii infection in 
the eye, but the choroid, vitreous and anterior chamber 
are also involved. The choroid is secondarily affected, al-
though choroidal lesions do not occur in the absence of ret-
inal infection. An intense secondary iridocyclitis may also 
be present (Nussenblatt & Belfort 1994, Holland 2004). 
In addition, the optic nerve head can also be involved in 
ocular toxoplasmosis (Eckert et al. 2007) (Fig. 5).
Elderly or immunosuppressed patients may pres-
ent with more aggressive bilateral or multifocal disease 
(Fig. 6). Elderly patients recently infected with T. gon-
dii may have a higher prevalence of ocular involvement. 
Other atypical presentations include punctate outer retinal 
toxoplasmosis, retinal vasculitis, retinal vascular occlu-
sions, rhegmatogenous with serous retinal detachments, 
unilateral pigmentary retinopathy mimicking retinitis 
pigmentosa, neuroretinitis and additional forms of op-
tic neuropathy, peripheral retinal necrosis and scleritis 
(Smith & Cunningham 2002, Bonfioli & Orefice 2005). 
Fig. 1: inactive old ocular toxoplasmosis lesions with vitreous strand 
and vasculitis. 
Fig. 2: retinal scar with typical features of recurrent ocular toxo-
plasmosis.
Fig. 3: ocular toxoplasmosis with old pigmented scar and recurrence 
inferior to the macula.
Fig. 4: inferior area of retinochoroiditis and diffuse vasculitis.
Ocular complications seen more frequently in chil-
dren, include choroidal neovascularisation, cataract, 
glaucoma, optic nerve atrophy and retinal detachment 
(Bosch-Driessen et al. 2000). An association between 
ocular toxoplasmosis and Fuchs’ heterochromic cyclitis 
has been described (Toledo de Abreu et al. 1982) and 
confirmed by several researchers (Schwab 1991, La Hey 
& Baarsma 1993, Ganesh et al. 2004).
The appearance of toxoplasmic retinochoroiditis le-
sions varies. The duration and intensity may be related 
to the host, parasite, or environmental factors (Holland 
et al. 1996). The genotype of the infecting parasite ap-
pears to be an important determinant of disease severity 
in immunocompetent patients (Holland 2004).
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Retinal vasculitis and associated inflammatory re-
actions may be the lone ophthalmic disorder during the 
early stages of a newly acquired T. gondii infection. Later 
development of retinitis or scars consistent with toxo-
plasmic retinochoroiditis in the same eyes suggests that 
the initial isolated inflammation may have been caused 
by the parasites. These cases may have implications for 
understanding the original source of retinal infection in 
patients who have recurrent toxoplasmic retinochoroidi-
tis and could have implications for novel treatments of 
newly acquired T. gondii infections (Silveira et al.2001).
Recurrent toxoplasmic retinochoroiditis is not associ-
ated with systemic symptoms and the risk of recurrence 
may be influenced by patient age. Ocular lesions may 
first develop many years after T. gondii infection and are 
often asymptomatic (Nussenblatt & Belfort 1994). 
Transplacental transmission of T. gondii to the foetus 
during pregnancy is another important route of infection. 
The mother can transmit toxoplasmosis to the foetus if 
infected primarily by T. gondii during pregnancy or a 
few months prior to conception (Montoya & Liesenfeld 
2004). The foetal infection can result in visual loss, hear-
ing loss, mental and psychomotor retardation, seizures, 
haematological abnormalities, hepatosplenomegaly and/
or death (Montoya & Remington 2008). Retinochoroi-
dal scars are the most characteristic manifestation of a 
congenital or prenatal infection (Mets & Chhabra 2008) 
(Fig. 7). Mothers who become infected during the first 
trimester of gestation have a decreased risk of congeni-
tal transmission, but more severe consequences for the 
foetus when compared with the third trimester (Mon-
toya & Remington 2008). Paediatricians, parents and el-
der children with congenital infections should be aware 
that late-onset retinal lesions can occur many years after 
birth, but the overall ocular prognosis of congenital toxo-
plasmosis is satisfactory when the infection is identified 
early and treated accordingly (Wallon et al. 2004). 
Severe bilateral impairment occurred in 9% of chil-
dren with congenital toxoplasmic retinochoroiditis. Half 
of the children with a posterior pole lesion and one in 
six of those with peripheral lesions alone were visually 
impaired in the affected eye (Tan et al. 2007). Numerous 
children with congenital toxoplasmosis have substantial 
retinal damage at birth and consequent loss of vision. 
Nevertheless, vision may be remarkably good, even in 
the presence of large macular scars. Active lesions be-
come quiescent with treatment and may recur at any age 
(Mets et al. 1997).
In one study evaluating 430 children treated for con-
genital toxoplasmosis, ocular involvement was present in 
30% of the cohort after a median follow-up of 12 years. 
The overall functional prognosis of congenital toxoplas-
mosis was better than would be predicted on the basis of 
literature findings, with only two of the 130 children suf-
fering bilateral visual impairment (Kodjikian et al. 2006). 
Fig. 7: retinal scars linked by vitreous strand in congenital  toxoplasmosis.
Fig. 5: optic disk involvement with macular exudates in a case of ocu-
lar toxoplasmosis.
Fig. 6: toxoplasmic scar and active CMV retinitis in a patient with  AIDS.
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Although it is classically known that only during 
acute infection the mother could transmit the infection 
to the foetus, there are a few reports supporting the pos-
sibility that chronically infected women may be trans-
mitting the disease congenitally (Silveira et al. 2003). 
The diagnosis of ocular toxoplasmosis is typically clini-
cal. There is no reliable diagnostic test to identify toxoplas-
mic uveitis. The presence of anti T. gondii IgG antibodies 
does not confirm the toxoplasmic aetiology, but a negative 
IgG generally discards the possibility. Such antibodies can 
often persist at high titers for years after the acute infec-
tion and there is a high prevalence of such antibodies in the 
general population (Ongkosuwito et al. 1999). 
Pathological diagnosis of ocular toxoplasmosis can 
be established by identifying the cysts in biopsies stained 
with haematoxylin and eosin, polyclonal or monoclonal 
antibodies by immunohistochemistry (Rao & Font 1977), 
or by polymerase chain reaction (PCR) (Brezin et al. 1990). 
Histologically, ocular toxoplasmosis typically presents as 
extensive granulomatous inflammatory infiltration of the 
choroid and areas of necrosis of Bruch’s membrane (Bel-
fort et al. 2008, unpublished observations). 
T. gondii DNA has been identified in ocular tissue sec-
tions of patients with presumed toxoplasmic retinochor-
oiditis using PCR techniques, even when typical tissue 
cysts are not identified during histopathologic examina-
tion (Brézin et al. 1990, Ongkosuwito et al. 1999).
Examination of vitreous fluid using PCR in patients 
where toxoplasmosis is considered in the differential 
diagnosis but in whom the presentation is atypical, is a 
useful diagnostic aid (Montoya et al. 1999, Rothova et al. 
2008). To facilitate genotyping of T. gondii in vitreous 
fluid of patients with severe or atypical ocular toxoplas-
mosis, PCR followed by restriction fragment length poly-
morphism assays were developed (Grigg et al. 2001). 
One study compared three biological methods, im-
munoblotting/Western blotting, the calculation of the 
Goldmann-Witmer coefficient and PCR for the diagno-
sis of ocular toxoplasmosis in the aqueous humor and 
serum samples. The authors showed that the combina-
tion of all three techniques improved the sensitivity of 
diagnosis to 97% (Fekkar et al. 2008).
Alternatively, nested-PCR (nPCR) can be a reliable 
diagnostic technique for ocular toxoplasmosis because of 
the amount of specimen required, speed, cost effective-
ness, high sensibility and high specificity to detect of 
T. gondii DNA in the intraocular fluids (Calderaro et al. 
2006, Mahalakshmiet al. 2006).
More recently, real-time PCR has been replacing 
nPCR as a rapid and sensitive technique for quantita-
tively evaluating ocular samples for the presence of in-
fectious pathogens (Lin et al. 2000, Dworkin et al. 2002, 
Rothova et al. 2008). 
Laboratory confirmation of the diagnosis is also 
thwarted by marked individual variations in the time 
elapsing between the onset of clinical symptoms and 
the activation of specific antibody production. This 
difficulty results in a high proportion of false negative 
results (Garweg 2005).
Treatment of ocular toxoplasmosis
Ocular toxoplasmosis therapy includes antimicro-
bial drugs with or without the presence of corticoste-
roids. Several drugs have been proposed including py-
rimethamine, sulfadiazine, spiramycin, clindamycin 
and trimethoprim-sulfamethoxazol (Pleyer et al. 2007, 
Antoniazzi et al. 2008).
Results of a study comparing three drug combina-
tions: (i) association of pyrimethamine, sulphadiazine 
and corticosteroids; (ii) association of clindamycin, sul-
phadiazine and corticosteroids; (iii) association of co-
trimoxazole (trimethoprim and sulphamethoxazole) and 
corticosteroids, showed no difference in the resolution of 
inflammatory activities. However the most common side 
effects were associated with pyrimethamine medication 
and included hematologic complications, such as throm-
bocytopenia and leucopenia, despite folinic acid supple-
mentation (Rothova et al. 1989). The same group studied 
in 1993 showed a reduction in size of the retinal inflam-
matory lesion for 49% of the pyrimethamine-treated pa-
tients (17 of 35) compared to 20% of the untreated pa-
tients (8 of 41). However, the most frequent occurrence 
of side effects was also associated with pyrimethamine 
medication (26%, 9 of 35) (Rothova et al. 1993).
The combination of pyrimethamine, sulfadiazine and 
corticosteroids, which is considered “classic” or specific 
therapy for ocular toxoplasmosis, is the most common 
drug combination currently used to treat toxoplasmosis 
(Montoya & Liesenfeld 2004).
Patients with active toxoplasmosis may also be treat-
ed with trimethoprim-sulfamethoxazole (Bactrim), with 
or without adjunctive clindamycin and prednisone for 
4-6 weeks. Trimethoprim-sulfamethoxazole appears to 
be a safe and effective substitute for sulfadiazine, py-
rimethamine and folinic acid in treating for the treat-
ment of ocular toxoplasmosis (Opremcak et al. 1992, 
Soheilian et al. 2005).
The pyrimethamine and azithromycin drug combi-
nation was shown to be similar to the standard treatment 
with pyrimethamine and sulfadiazine. However, the fre-
quency and severity of adverse effects was significantly 
lower with the regimen containing pyrimethamine and 
azithromycin. Multidrug therapy containing the combi-
nation of pyrimethamine and azithromycin appears to be 
an acceptable alternative treatment for sight-threatening 
ocular toxoplasmosis (Bosch-Driessen et al. 2002).
The causes of recurrences in ocular toxoplasmo-
sis remain unknown. The causes may be related to the 
rupture of the dormant retinal cyst (Abreu et al. 1987) 
or toxoplasma circulating in peripheral blood (Silveira 
et al., unpublished observations). Recurrent toxoplas-
mic retinochoroiditis remains a major health crisis and 
can be associated with severe morbidity if the disease 
extends to structures critical for vision, including the 
macula and optic disk. Severe morbidity may also oc-
cur if there is damage to the eye from inflammation or 
if there are complications such as retinal detachment or 
neovascularisation. In patients with frequent recurren-
ces, long-term intermittent treatment with trimethoprim 
(160 mg)/sulfamethoxazole (800 mg), one tablet three 
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times a week reduced the rate of recurrent toxoplasmic 
retinochoroiditis from 23.8-6.6% (Silveira et al. 2002). 
Traditional short-term treatment of active toxoplasmic 
retinochoroiditis lesions does not prevent subsequent re-
currences. Various short-term therapeutic approaches had 
no effect on visual outcomes or future recurrence rates, 
with the exception of a poor visual outcome for patients 
who received corticosteroids without anti parasitic drugs 
(Bosch-Driessen et al. 2002). Studies have yet to confirm 
the relationship between systemic corticosteroid use and 
reactivation of toxoplasmosis (Morhun et al. 1996). 
Intravitreal clindamycin injection and possibly ste-
roids may be indicated for patients that have contrain-
dication of systemic therapy specific for toxoplasmosis 
(Aggio et al. 2006, Sobrin et al. 2007). Sobrin et al (2007) 
showed that intravitreal clindamycin injection, alone or 
in conjunction with pars plana vitrectomy, was associ-
ated with resolution of toxoplasmic retinochoroiditis. On 
the other hand, intravitreal injections of clindamycin and 
dexamethasone (Kishore et al. 2001) with subconjuncti-
val injections of clindamycin (Colin & Harie 1989) ap-
pear to be an interesting useful alternative in the choice 
of an anti-toxoplasmic ocular therapy.
Treatment with spiramycin should be initiated im-
mediately after diagnosis of recently acquired maternal 
infection (Montoya & Liesenfeld 2004). The literature 
shows the lack of efficacy of short-term treatments for 
ocular disease as well as the long-term prenatal treat-
ments on foetal transmission rate and the severity of 
congenital disease (Rothova 2003).
Ocular toxoplasmosis remains a disease in which 
most concepts are unfortunately not based on scientific 
evidence. Treatments often change according to induc-
tion and seduction of speakers and investigators instead 
of objective findings based on reasoning and deduction. 
Little is known, and much less of what is known is true.
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